- Rinri Therapeutics, a Sheffield, England, UK-based biotechnology company developing a novel stem cell therapy to restore hearing, raised a total of £10m in funding
- Backers included existing investors Boehringer Ingelheim Venture Fund (BIVF), UCB Ventures and BioCity alongside the UK Government Future Fund
- The proceeds will also support the development of the company’s novel stem cell therapy to reverse sensorineural hearing loss (SNHL)
- Rinri Therapeutics is a private biotechnology company developing advanced stem cell-based therapeutics to restore hearing
- The company’s technology seeks to reverse sensorineural hearing loss (SNHL) through the repair of the damaged cytoarchitecture in the inner ear
- Then the technology is based on innovative research into auditory stem cells led by Professor Marcelo Rivolta at the University of Sheffield from where the company spun out
